• Heritage Cannabis Holdings Corp. (CANN) has completed its first production run and shipment of products to dispensaries in the State of Missouri
  • Heritage Cannabis’ products, including  RAD distillate vapes, RAD live resin and live rosin, are now available in both Missouri and West Virginia
  • David Schwede, CEO of Heritage, sat down with Sabrina Cuthbert to discuss the news
  • Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S.
  • Heritage Cannabis Holdings Corp. (CANN) opened trading at C$0.025

Heritage Cannabis Holdings Corp. (CANN) has completed its first production run and shipment of products to dispensaries in the State of Missouri.

Heritage Cannabis’ products, including  RAD distillate vapes, RAD live resin and live rosin, are now available in Missouri and West Virginia.

Heritage Cannabis CEO David Schwede sat down with Sabrina Cuthbert to discuss the news.

“With the recent successful legalization of cannabis in the state of Missouri, we are thrilled to be ahead of the curve with products on shelves ready to serve medical and recreational consumer groups in the State. Our U.S. strategy is adding a high gross margin revenue stream to the business using an asset-light approach in partnership with existing local license holders. As a market leader and innovator, we continue to launch new products to capture a substantial share of early shelf space in these burgeoning markets.”

Heritage Cannabis is a leading cannabis company with an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, Thrifty, feelgood., the CB4 suite of medical products in Canada and ArthroCBD in the U.S.

Heritage Cannabis Holdings Corp. (CANN) opened trading at C$0.025.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.